The use of fluvastatin in cardiovascular risk management

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 8, 2008, Pages 1407-1414

  McDonald, Kenneth J ^a   Jardine, Alan G ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cardiovascular disease; Cholesterol; Fluvastatin; Hyperlipidaemia; Statin

Indexed keywords

ATORVASTATIN; CLOPIDOGREL; CYCLOSPORIN; DRUG METABOLIZING ENZYME; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LESCOL XL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TACROLIMUS; HYPOCHOLESTEROLEMIC AGENT; INDOLE DERIVATIVE; MONOUNSATURATED FATTY ACID;

ACUTE HEART INFARCTION; AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSLIPIDEMIA; EVENING DOSAGE; GASTROINTESTINAL DISEASE; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER FUNCTION TEST; LIVER TOXICITY; MUSCLE DISEASE; MYALGIA; MYOSITIS; PATENT; PATIENT COMPLIANCE; PHARMACODYNAMICS; PLEIOTROPY; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; REVIEW; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; RISK REDUCTION; SIDE EFFECT; COMPARATIVE STUDY; DRUG INTERACTION; RISK FACTOR;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; FATTY ACIDS, MONOUNSATURATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 45549092970     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.8.1407     Document Type: Review

References (47)

1. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screens of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256(20):2823-8
2. Fletcher B, Berra K, Ades P, et al. Managing abnormal blood lipids: a collaborative approach. Circulation 2005;112(20):3184-209
3. Grundy SM, Cleeman JI, Metz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110(2):227-39
4. Statins for the prevention of cardiovascular events. National Institute for Clinical Excellence Technology Appraisal Guidance no. 94, 2006. Available from: http//www.nice.org.uk
5. Manuel DG, Kwong K, Tanuseputro P, et al. Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study. BMJ 2006;332(7555):1419
6. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22(7):554-72
7. Petrella RJ, Merikle E, Jones J. Prevalence and treatment of dyslipidemia in Canadian primary care: a retrospective cohort analysis. Clin Ther 2007;29(4):742-50
8. Penning-Van Beest FJ, Termorshuizen F, Goettsch WG, et al. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J 2007;28(2):154-9
9. Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007;72(3):247-59
10. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326(7404):1423
11. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001;292(5519):1160-4
12. Schaefer JR, Schweer H, Ikewaki K, et al. Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis 1999;144(1):177-84
13. Dujovne CA, Davidson MH. Fluvastatin administration at bedtime versus with the evening meal: a multicenter comparison of bioavailability, safety, and efficacy. Am J Med 1994;96(6A):37S-40S
14. Corsini A. Fluvastatin: effects beyond cholesterol lowering. J Cardiovasc Pharmacol Ther 2000;5(3):161-75
15. Hillyard DZ, Cameron AJ, McIntyre AH, et al. Inhibition of proliferation and signalling mechanisms in human lymphocytes by fluvastatin. Clin Exp Pharmacol Physiol 2002;29(8):673-8
16. Hillyard DZ, Jardine AG, McDonald KJ, Cameron AJ. Fluvastatin inhibits raft dependent Fcgamma receptor signalling in human monocytes. Atherosclerosis 2004;172(2):219-28
17. John S, Schlaich M, Langenfeld M, et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation 1998;98(3):211-6
18. Hillyard DZ, Nutt CD, Thomson J, et al. Status inhibit NK cell cytotoxicity by membrane raft depletion rather than inhibition of isoprenylation. Atherosclerosis 2007;191(2):319-25
19. Guillot F, Misslin P, Lemaire M. Comparison of fluvastatin and lovastatin blood-brain barrier transfer using in vitro and in vivo methods. J Cardiovasc Pharmacol 1993;21(2):339-46
20. Fischer V, Johanson L, Heitz F, et al. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Dispos 1999;27(3):410-6
21. Kirchheiner J, Kudlicz D, Meisel C, et al. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin Pharmacol Ther 2003;74(2):186-94
22. Appel-Dingemanse S, Smith T, Merz M. Pharmacokinetics of fluvastatin in subjects with renal impairment and nephrotic syndrome. J Clin Pharmacol 2002;42(3):312-8
23. Peters TK, Mehra M, Muratti EN. Efficacy and safety of fluvastatin in hypertensive patients. An analysis of a clinical trial database. Am J Hypertens 1993;6(11 Part 2):340S-345S
24. Insull W Jr, Black D, Dujovne C, et al. Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia. Arch Intern Med 1994;154(21):2449-55
25. Herd JA, Ballantyne CM, Farmer JA, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997;80(3):278-86
26. Serruys PW, De Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;287(24):3215-22
27. Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003;361(9374):2024-31
28. Holdaas H, Fellstrom B, Cole E, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 2005;5(12):2929-36
29. Olsson AG, Pauciullo P, Soaka V, et al. Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial. Clin Ther 2001;23(1):45-61
30. Ballantyne CM, Pazzucconi F, Pinto X, et al. Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis. Clin Ther 2001;23(2):177-92
31. Barilla D, Prasad P, Hubert M, Gumbhir-Shah K. Steady-state pharmacokinetics of fluvastatin in healthy subjects following a new extended release fluvastatin tablet, Lescol XL. Biopharm Drug Dispos 2004;25(2):51-9
32. Ballantyne CM, McKenney J, Trippe BS. Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemia. Am J Cardiol 2000;86(7):759-63
33. Winkler K, Ablethauser CB, Gimpelewicz C, et al. Risk reduction and tolerability of fluvastatin in patients with the metabolic syndrome: a pooled analysis of thirty clinical trials. Clin Ther 2007;29(9):1987-2000
34. Holdaas H, Wanner C, Abletshauser C, et al. The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials. Int J Cardiol 2007;117(1):64-74
35. Holdaas H, Jardine AG, Wheeler DC, et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney Int 2001;60(5):1990-7
36. Bruckert E, Verpilleux MP, Dejager S, Isaacsohn J. Comparison of efficacy and safety assessment of fluvastatin in patients < 65 years versus > or = 65 years of age. Am J Cardiol 2005;96(8):1142-8
37. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006;97(8A):52C-60C
38. Stein EA, Ballantyne CM, Windler E, et al. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol 2008;101(4):490-6
39. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a meta-analysis. Clin Ther 2006;28(1):26-35
40. Conforti A, Magro L, Moretti U, et al. Fluvastatin and hepatic reactions: a signal from spontaneous reporting in Italy. Drug Saf 2006;29(12):1163-72
41. Jardine A, Holdaas H. Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience. J Clin Pharm Ther 1999;24(6):397-408
42. Holdaas H, Hagen E, Asberg A, et al. Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients. Int J Clin Pharmacol Ther 2006;44(4):163-71
43. Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 1998;34(2):155-62
44. Papadakis JA. Ganotakis ES, Jagroop IA, et al. Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. Int J Cardiol 1999;69(3):237-44
45. Derosa G, Cicero AE, Bertone G, et al. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease a I2-month, randomized, double-blind, controlled trial. Clin Ther 2004;26(10):1599-607
46. Ayalasomayajula SP, Vaidyanathan S, Kemp C, et al. Effect of clopidogrel on the steady-state pharmacokinetics of fluvastatin. J Clin Pharmacol 2007;47(5):613-9
47. Serruys PW, Foley DP, Jackson G, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the Fluvastatin Angiographic Restenosis (FLARE) Trial. Eur Heart J 1999;20(1):58-69